Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: A TBNET/RESIST-TB consensus statement

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 1, 2016, Pages 24-42

  Dominguez, J ^a   Boettger, E C ^b   Cirillo, D ^c   Cobelens, F ^d   Eisenach, K D ^e   Gagneux, S ^f   Hillemann, D ^g   Horsburgh, R ^h   Molina Moya, B ^a   Niemann, S ^g   Tortoli, E ^c   Whitelaw, A ⁱ   Lange, C ^g,j,k  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF BASEL   (Switzerland)

^g RESEARCH CENTER BORSTEL   (Germany)

^h BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ STELLENBOSCH UNIVERSITY   (South Africa)

^j UNIVERSITY OF NAMIBIA   (Namibia)

^k KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Clinician guidance; Interpretation; Molecular methods

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; LINEZOLID; MEROPENEM; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

BACTERIAL GENOME; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG RESISTANCE; DRUG SENSITIVITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IN VITRO STUDY; MEDICAL DECISION MAKING; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS CONTROL; CONSENSUS DEVELOPMENT; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84951962885     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0221     Document Type: Review

References (195)

1. World Health Organization. Global tuberculosis control, 2014. WHO/HTM/TB/2014.08. Geneva. Switzerland: WHO, 2014.
2. Gandhi N R, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
3. Velayati A A, Masjedi M R, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136: 420-425.
4. Wilson M L. Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. Arch Pathol Lab Med 2013; 137: 812-819.
5. Niemann S, Supply P. Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches. Cold Spring Harb Perspect Med 2014; 4: a021188.
6. Miotto P, Cabibbe A M, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012; 40: 690-698.
7. Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012; 50: 1264-1269.
8. w MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014; 10: CD010705.
9. Walker T M, Kohl T A, Omar S V, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-1202.
10. Lange C, Abubakar I, Alffenaar J W, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
11. Almeida Da Silva P E, Palomino J C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011; 66: 1417-1430.
12. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279.
13. Falzon D, Jaramillo E, Schunemann H J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
14. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 2011; 18: e29-34.
15. Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLOS ONE 2011; 6: e27610.
16. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
17. Sturdy A, Goodman A, Jose R J, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815-1820.
18. Van der Walt M, Lancaster J, Odendaal R, Davis J G, Shean K, Farley J. Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients. PLOS ONE 2013; 8: e58817.
19. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLOS MED 2012; 9: e1001300.
20. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
21. Dooley K E, Nuermberger E L, Diacon A H. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 2013; 8: 579-585.
22. Salfinger M, Migliori G B. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015; 45: 317-321.
23. Somoskovi A, Bruderer V, Homke R, Bloemberg G V, Bottger E C. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554-557.
24. Zhang Y, Yew W W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330.
25. Shimao T. Drug resistance in tuberculosis control. Tubercle 1987; 68: 5-18.
26. Gagneux S, DeRiemer K, Van T, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-2873.
27. de Steenwinkel J E, ten Kate M T, de Knegt G J, et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR-TB. Emerg Infect Dis 2012; 18: 660-663.
28. Ford C B, Shah R R, Maeda M K, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784-790.
29. Merker M, Kohl T A, Roetzer A, et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLOS ONE 2013; 8: e82551.
30. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
31. Vareldzis B P, Grosset J, de Kantor I, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle Lung Dis 1994; 75: 1-7.
32. Muller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013; 29: 160-169.
33. Sun G, Luo T, Yang C, et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012; 206: 1724-1733.
34. Zignol M, Dara M, Dean A S, et al. Drug-resistant tuberculosis in the WHO European Region: An analysis of surveillance data. Drug Resist Updat 2013; 16: 108-115.
35. Bonnet M, Pardini M, Meacci F, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLOS ONE 2011; 6: e23081.
36. Cox H S, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359: 2398-2400.
37. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
38. Dye C, Williams B G, Espinal M A, Raviglione M C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
39. Gagneux S, Long C D, Small P M, Van T, Schoolnik G K, Bohannan B J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
40. Andersson D I, Levin B R. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-493.
41. Bö ttger E C, Springer B. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 2008; 167: 141-148.
42. Bö ttger E C, Springer B, Pletschette M, Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998; 4: 1343-1344.
43. Sander P, Springer B, Prammananan T, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46: 1204-1211.
44. Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012; 44: 106-110.
45. de Vos M, Muller B, Borrell S, et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013; 57: 827-832.
46. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson D I, Bottger E C. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-840.
47. Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014; 46: 279-286.
48. Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011; 17: 815-820.
49. Drobniewski F, Rüsch-Gerdes S, Hoffner S, Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1): report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007; 13: 1144-1156.
50. Kim S J. Drug susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569.
51. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006; 44: 20-28.
52. th ed. Philadelphia, PA, USA: Lippincott Williams and Wilkins, 2005.
53. th ed. Washington DC, USA: ASM Press, 2003.
54. nd ed. CLSI document M24-A2. Wayne PA: CLSI, 2011.
55. Angeby K, Jureen P, Kahlmeter G, Hoffner S E, Schon T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012; 90: 693-698.
56. Böttger E C. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms and laboratory susceptibility testing. In: Donald P R, van Helden P D, eds. Antituberculosis chemotherapy. Progress in respiratory research Vol 40. Karger, 2011: pp 128-144.
57. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. Geneva, Switzerland: WHO, 2008.
58. World Health Organization and Fondation Mérieux. TB diagnostics and laboratory services: actions for care delivery and sustainability. 4th Annual Global Laboratory Initiative. Geneva, Switzerland: WHO, 2012.
59. Angra P K, Taylor T H, Iademarco M F, Metchock B, Astles J R, Ridderhof J C. Performance of tuberculosis drug susceptibility testing in US laboratories from 1994 to 2008. J Clin Microbiol 2012; 50: 1233-1239.
60. Horne D J, Pinto L M, Arentz M, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line anti-tuberculosis drugs. J Clin Microbiol 2013; 51: 393-401.
61. Chang K C, Yew W W, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011; 55: 4499-4505.
62. Dormandy J, Somoskövi A, Kreiswirth B N, Driscoll J R, Ashkin D, Salfinger M. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460 TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007; 131: 497-501.
63. Werngren J, Sturegard E, Jureen P, Angeby K, Hoffner S, Schon T. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012; 56: 1253-1257.
64. Kruuner A, Yates M D, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first-and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-818.
65. Lin S Y, Desmond E, Bonato D, Gross W, Siddiqi S. Multicenter evaluation of BACTEC MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009; 47: 3630-3634.
66. Böttger E C. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-1134.
67. Van Deun A, Aung K J, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640.
68. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-1491.
69. Springer B, Calligaris-Maibach R C, Ritter C, Bö ttger E C. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J Clin Microbiol 2008; 46: 4064-4067.
70. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger E C. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-1780.
71. Cambau E, Viveiros M, Machado D, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 2015; 70: 686-696.
72. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO, 2008.
73. World Health Organization. Policy statement: automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011.
74. w MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1: CD009593.
75. Van Deun A, Aung K J, Hossain A, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015; 19: 185-190.
76. Friedrich S O, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1: 462-470.
77. Barnard M, Warren R, Gey Van Pittius N, et al. Genotype MTBDRsl line-probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186: 1298-1305.
78. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-1772.
79. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43: 3699-3703.
80. Jacobson K R, Theron D, Kendall E A, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56: 503-508.
81. Ritter C, Lucke K, Sirgel F A, et al. Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains. J Clin Microbiol 2014; 52: 940-946.
82. Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType MTBDRsl for molecular detection of second-line drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2012; 50: 30-36.
83. Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008; 46: 3660-3667.
84. Coker R J. Review: multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health 2004; 9: 25-40.
85. Gillespie S H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46: 267-274.
86. Fujirebio. INNO LiPA Rif.TB product insert. Ghent, Belgium: Fujirebio, 2006. http://tbevidence.org/documents/rescentre/sop/INNOLiPARifTB.pdf.
87. Hain Lifescience, Genotype MTBDRplus product insert. Nehren, Germany: Hain, 2012. http://www.hain-lifescience. de/include-datei/kundenmodule/packungsbeilage/download. php?id(14);398. Accessed September 2015.
88. Autoimmun Diagnostika GMBH. AID TB Resistance assay product insert. Strassberg, Germany: Autoimmun Diagnostika, 2013. http://www.aid-diagnostika.com/english/kits/downloads/25092013/RDB2185-PCR-TBRES.pdf. Accessed September 2015.
89. Rigouts L, Gumusboga M, de Rijk W B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51: 2641-2645.
90. Williamson D A, Roberts S A, Bower J E, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-220.
91. Yuan X, Zhang T, Kawakami K, et al. Molecular characterization of multidrug-and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol 2012; 50: 2404-2413.
92. Miotto P, Piana F, Cirillo D M, Migliori G B. GenoType MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 393-394.
93. Fenner L, Egger M, Bodmer T, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3047-3053.
94. Georghiou S B, Magana M, Garfein R S, Catanzaro D G, Catanzaro A, Rodwell T C. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLOS ONE 2012; 7: e33275.
95. Sreevatsan S, Pan X, Stockbauer K E, Williams D L, Kreiswirth B N, Musser J M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996; 40: 1024-1026.
96. Nhu N T, Lan N T, Phuong N T, Chau N, Farrar J, Caws M. Association of streptomycin resistance mutations with level of drug resistance and Mycobacterium tuberculosis genotypes. Int J Tuberc Lung Dis 2012; 16: 527-531.
97. Via L E, Cho S N, Hwang S, et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol 2010; 48: 402-411.
98. Plinke C, Cox H S, Kalon S, Doshetov D, Rü sch-Gerdes S, Niemann S. Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb) 2009; 89: 448-452.
99. Molina-Moya B, Lacoma A, Prat C, et al. AID TB resistance line probe assay for rapid detection of resistant Mycobacterium tuberculosis in clinical samples. J Infect 2015; 70: 400-408.
100. Rienthong S, Boonin C, Chaiyasirinrote B, et al. Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand. Int J Tuberc Lung Dis 2015; 19: 817-822.
101. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update WHO/HTM/TB/2013. 16. Geneva, Switzerland: WHO, 2013.
102. Molina-Moya B, Lacoma A, Prat C, et al. Diagnostic accuracy study of multiplex PCR for detecting tuberculosis drug resistance. J Infect 2015; 71: 220-230.
103. Ali A, HasanZ, McNerneyR, et al. Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. PLOS ONE 2015; 10: e0117771.
104. Brown A C, Bryant J M, Einer-Jensen K, et al. Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol 2015; 53: 2230-2237.
105. Banu S, Rahman S M, Khan M S, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol 2014; 52: 156-163.
106. Bwanga F, Hoffner S, Haile M, Joloba M L. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009; 9: 67.
107. Chang K C, Yew W W, Chan R C. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010; 65: 1551-1561.
108. Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using GenoType MTBDRsl assay: a meta-analysis. PLOS ONE 2013; 8: e55292.
109. Hillemann D, Rü sch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640.
110. Garcia-Sierra N, Lacoma A, Prat C, et al. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2011; 49: 3683-3686.
111. Dominguez J, Blanco S, Lacoma A, Garcia-Sierra N, Prat C, Ausina V. [Utility of molecular biology in the microbiological diagnosis of mycobacterial infections]. Enferm Infecc Microbiol Clin 2008; 26 (Suppl 9): 33-41.
112. Lacoma A, Molina-Moya B, Prat-Aymerich C, et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance. Diagn Microbiol Infect Dis 2015 Jul 11. [Epub ahead of print]
113. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
114. Zhang H, Li D, Zhao L, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013; 45: 1255-1260.
115. Hoshide M, Qian L, Rodrigues C, et al. Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 2014; 52: 1322-1329.
116. Sun Y J, Luo J T, Wong S Y, Lee A S. Analysis of rpsL and rrs mutations in Beijing and non-Beijing streptomycin-resistant Mycobacterium tuberculosis isolates from Singapore. Clin Microbiol Infect 2010; 16: 287-289.
117. Gagneux S, Burgos M V, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLOS Pathog 2006; 2: e61.
118. Cohen T, Becerra M C, Murray M B. Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist 2004; 10: 280-285.
119. Hazbon M H, Brimacombe M, Bobadilla del Valle M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-2649.
120. Musser J M, Kapur V, Williams D L, Kreiswirth B N, van Soolingen D, van Embden J D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996; 173: 196-202.
121. Rouse D A, Li Z, Bai G H, Morris S L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2472-2477.
122. Morlock G P, Metchock B, Sikes D, Crawford J T, Cooksey R C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-3805.
123. Huyen M N, Cobelens F G, Buu T N, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 2013; 57: 3620-3627.
124. Tolani M P, D'Souza D T, Mistry N F. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 2012; 12: 9.
125. Machado D, Perdigao J, Ramos J, et al. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 2013; 68: 1728-1732.
126. Muller B, Streicher E M, Hoek K G, et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011; 15: 344-351.
127. Campbell P J, Morlock G P, Sikes R D, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-2041.
128. Ramaswamy S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis 1998; 79: 3-29.
129. Rodwell T C, Valafar F, Douglas J, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014; 52: 781-789.
130. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 719-723.
131. Bodmer T, Zurcher G, Imboden P, Telenti A. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345-348.
132. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10: 662-665.
133. Huitric E, Werngren J, Jureen P, Hoffner S. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2006; 50: 2860-2682.
134. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996; 40: 1053-1056.
135. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650.
136. Yang B, Koga H, Ohno H, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-628.
137. Jou R, ChenH Y, ChiangCY, Yu M C, Su I J.Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan. J Clin Microbiol 2005; 43: 1390-1394.
138. Sirgel F A, Warren R M, Bottger E C, Klopper M, Victor T C, van Helden P D. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLOS ONE 2013; 8: e59414.
139. Jo K W, Ji W, Hong Y, et al. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 2013; 107: 292-297.
140. van Ingen J, Aarnoutse R, de Vries G, Boeree M J, van Soolingen D. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-992.
141. van Ingen J, de Lange W C, Boeree M J, et al. XDR tuberculosis. Lancet Infect Dis 2011; 11: 585.
142. Siu G K, Zhang Y, Lau T C, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 730-733.
143. Bobadilla-del-Valle M, Ponce-de-Leon A, Arenas-Huertero C, et al. rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis 2001; 7: 1010-1013.
144. Evans J T, Parveen A, Smith G E, et al. Application of denaturing HPLC to rapidly identify rifampicin-resistant Mycobacterium tuberculosis in low-and high-prevalence areas. J Antimicrob Chemother 2009; 63: 295-301.
145. McCammon M T, Gillette J S, Thomas D P, et al. Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother 2005; 49: 2200-2209.
146. Al-Mutairi N M, Ahmad S, Mokaddas E. Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis 2011; 15: 110-115.
147. Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-3506.
148. Ereqat S, Bar-Gal G K, Nasereddin A, et al. Pulmonary tuberculosis in the West Bank, Palestinian Authority: molecular diagnostic approach. Trop Med Int Health 2011; 16: 360-367.
149. Yuen L K, Leslie D, Coloe P J. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37: 3844-3850.
150. Plinke C, Walter K, Aly S, Ehlers S, Niemann S. Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo. Antimicrob Agents Chemother 2011; 55: 2891-2896.
151. Safi H, Fleischmann R D, Peterson S N, Jones M B, Jarrahi B, Alland D. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 103-108.
152. Sirgel F A, Tait M, Warren R M, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 2012; 18: 193-197.
153. StarksA M, Gumusboga A, Plikaytis B B, ShinnickT M, Posey J E. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53: 1061-1066.
154. Sirgel FA, Warren RM, Streicher E M, Victor TC, van Helden P D, Bottger E C. embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis. Chemotherapy 2012; 58: 358-363.
155. Feuerriegel S, Oberhauser B, George A G, et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol 2012; 12: 90.
156. Johnson R, Jordaan A M, Pretorius L, et al. Ethambutol resistance testing by mutation detection. Int J Tuberc Lung Dis 2006; 10: 68-73.
157. Plinke C, Rüsch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2006; 50: 1900-1902.
158. Shi D, Li L, Zhao Y, et al. Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother 2011; 66: 2240-2247.
159. Tracevska T, Jansone I, Nodieva A, Marga O, Skenders G, Baumanis V. Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis. Res Microbiol 2004; 155: 830-834.
160. Alangaden G J, Kreiswirth B N, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1295-1297.
161. Feuerriegel S, Cox H S, Zarkua N, et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-3356.
162. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064-5068.
163. Sander P, Prammananan T, Bottger E C. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 1996; 22: 841-848.
164. Leung K L, Yip C W, Yeung Y L, et al. Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol 2010; 109: 2087-2094.
165. Akbergenov R, Shcherbakov D, Matt T, et al. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob Agents Chemother 2011; 55: 4712-4717.
166. Maus C E, Plikaytis B B, Shinnick T M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-3197.
167. Zaunbrecher M A, Sikes R D, Jr, Metchock B, Shinnick T M, Posey J E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-20009.
168. Finken M, Kirschner P, Meier A, Wrede A, Bottger E C. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993; 9: 1239-1246.
169. Meier A, Kirschner P, Bange F C, Vogel U, Bottger E C. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994; 38: 228-233.
170. Dobner P, Bretzel G, Rüsch-Gerdes S, et al. Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. Mol Cell Probes 1997; 11: 123-126.
171. Zhao L L, Chen Y, Chen Z N, et al. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother 2014; 58: 3475-3480.
172. Moure R, Tudo G, Medina R, et al. Detection of streptomycin and quinolone resistance in Mycobacterium tuberculosis by a low-density DNA array. Tuberculosis (Edinb) 2013; 93: 508-514.
173. Jnawali H N, Hwang S C, Park Y K, et al. Characterization of mutations in multi-and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn Microbiol Infect Dis 2013; 76: 187-196.
174. Chan R C, Hui M, Chan E W, et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59: 866-873.
175. Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother 2013; 57: 4496-500.
176. Kam K M, Yip C W, Cheung T L, Tang H S, Leung O C, Chan M Y. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006; 12: 7-11.
177. Poissy J, Aubry A, Fernandez C, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-4771.
178. Sirgel FA, WarrenR M, Streicher E M, Victor T C, van Helden P D, Bottger E C. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-1093.
179. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31: 115-121.
180. Maruri F, Sterling T R, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-831.
181. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 2014; 58: 364-369.
182. Foundation for Innovative New Diagnostics. Performance of Xpert MTB/RIF Version G4 assay. Geneva, Switzerland: FIND, 2011. http://www.stoptb.org/wg/gli/assets/documents/map/findg4cartridge.pdf. Accessed September 201
183. Lawn S D, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-361.
184. Canetti G, Le Lirzin M, Porven G, Rist N, Grumbach F. Some comparative aspects of rifampicin and isoniazid. Tubercle 1968; 49: 367-376.
185. van Ingen J, Aarnoutse R E, Donald P R, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 2011; 52: e194-199.
186. Gü nther G, van Leth F, Alexandru S, et al. TBNET study of multidrug-resistant tuberculosis in Europe. Emerg Infect Dis 2015; 21: 409-416.
187. Gü nther G, van Leth F, Altet N, et al. Beyond multidrug-resistant tuberculosis in Europe. A TBNET study. Int J Tuberc Lung Dis 2015. [In press].
188. Aktas E, Durmaz R, Yang D, Yang Z. Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey. Microb Drug Resist 2005; 11: 94-99.
189. Shafer R W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15: 247-277.
190. Tang M W, Shafer R W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72: e1-25.
191. Stucki D, Gagneux S. Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberculosis (Edinb) 2013; 93: 30-39.
192. Ocheretina O, Escuyer V E, Mabou M M, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLOS ONE 2014; 9: e90569.
193. Ho J, Jelfs P, Sintchencko V. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother 2013; 68: 2915-2920.
194. Koser C U, Comas I, Feuerriegel S, Niemann S, Gagneux S, Peacock S J. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay. Tuberculosis (Edinb) 2014; 94: 451-453.
195. Trauner A, Borrell S, Reither K, Gagneux S. Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy. Drugs 2014; 74: 1063-1072.